Alyftrek (vanzacaftor–tezacaftor–deutivacaftor), made by Vertex, represents the latest advance in CFTR modulator treatments that are transforming cystic fibrosis care by targeting the underlying cause ...

The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...

The new approach will ensure that high-impact devices, diagnostics and digital tools recommended by NICE, that meet the most urgent needs, are nationally reimbursed and made available across the NHS - ...

Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over. Last reviewed: 02 April 2025 Next review: ...

Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over. Last reviewed: 26 March 2025 Next review: This ...

Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of stage 1b to 3a non‑small‑cell lung cancer after complete tumour resection in adults. Last reviewed: 26 February 2025 ...

Evidence-based recommendations on durvalumab (Imfinzi) with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer in adults. Last reviewed: 19 February ...

Evidence-based recommendations on vadadustat (Vafseo) for treating symptomatic anaemia in adults having dialysis for chronic kidney disease. Last reviewed: 23 January 2025 Next review: This guidance ...

Evidence-based recommendations on anhydrous sodium thiosulfate (Pedmarqsi) for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours. Last ...

Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.

This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years.

NICE is unable to make a recommendation about the use in the NHS of enzalutamide (Xtandi) for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy. This is because ...